Are You An Anchor Study Expert?

Sanjoy T. Khan

David M. Brown

Lester B. Pearson

James S. Sykes

Compare Lucentis with Avastin and Eylea

Compare Ranibizumab and Aflibercept in the treatment of predominantly classic CNV (Choroidal Neovascularization)

Compare 0.3 and 0.5 mg doses of Ranibizumab in treating predominantly Occult CNV 

Compare Ranibizumab with Verteporfin Photodynamic Therapy (PDT) in treating predominantly classic CNV

Single country, triple masked, randomized study

Multi-Center, international, randomized, double masked, active treatment, controlled clinical trial.

North American, double masked, 12 month, randomized study

Global, single masked, retroactive clinical study

Number of injections over 24 months; change in Visual Acuity (VA) from baseline

% losing < 10 letters from baseline; % gaining 10 letters or more in VA; FA-assessed lesion characteristics 

% losing < 15 letters from baseline; % gaining 15 letters or more in VA; FA-assessed lesion characteristics 

% losing 5 or more letters; % gaining more than 10 letters; number of injections

Verteporfin PDT plus monthly sham intraocular injection; Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection ; Sham Verteporfin PDT plus monthly 0.5 mg Ranibizumab intraocular injection 

Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection ; Sham Verteporfin PDT plus monthly 0.5 mg Ranibizumab intraocular injection 

Monthly Avastin intraocular injection; Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection ; Sham Verteporfin PDT plus monthly 0.5 mg Ranibizumab intraocular injection

Verteporfin PDT plus monthly sham intraocular injection; Sham Verteporfin PDT plus monthly 0.3 mg Ranibizumab intraocular injection

198; 91%

243; 74%

423; 77%

514; 82%

0.3 mg Ranibizumab gained 10.7 letters on average; 0.5 mg Ranibizumab gained 8.1 on average; PDT LOST 9.8 letters on average 1

0.3 mg Ranibizumab gained 8.1 letters on average; 0.5 mg Ranibizumab gained 10.7 on average; PDT gained 9.8 letters on average

0.3 mg Ranibizumab gained 10.1 letters on average; 0.5 mg Ranibizumab gained 10.7 on average; PDT gained 10.8 letters on average

0.3 mg Ranibizumab gained 8.1 letters on average; 0.5 mg Ranibizumab gained 10.7 on average; PDT LOST 9.8 letters on average

Deterioration of all vision but not likely to be classified as legally blind

Temporary loss of the majority of non central vision

Permanent loss of the majority of central vision within 3 to 9 months of diagnosis

Loss of Drivers Licence 

A cardiovascular therapy could be used effectively in retina patients.

Off label use of Avastin for retina therapy was almost as effective as Ranibizumab.

This proved that anti-VEGf therapy was effective in preventing cataracts.

This was the 1st demonstration that a therapy could not only prevent further VA loss but also provide clinically meaningful improvement in VA in a substantial proportion of patients with predominately classic CNV.

Proportion of patients who at 12 months lost fewer than 15 letters (~3 lines) from baseline.

Proportion of patients who at 12 months gained more than 15 letters (~3 lines) from baseline.

Proportion of patients who at 12 months lost fewer than 15 letters (~3 lines) or gained more than 15 (~3 lines) letters from baseline.

Proportion of patients who had more than 100 microns of thinning of the retina from baseline at 12 months.

TREND

TREX

MARINA

FIREFOX

44

72

112

83

0

22

14

54

Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 5.2 letters

Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 2.1 letters

Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 11.1 letters

Ranibizumab 0.5mg: 4.6 letters; Ranibizumab 0.3 mg 2.9 letters

1.4%

2.2%

0.05%

0.0003%